The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1516
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Drugs for Hypertension
Revised 1/30/18: Information on new guidelines, and newly approved drugs have been changed.

Drugs available for treatment of chronic hypertension in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.

GUIDELINES — New guidelines for the treatment of hypertension published in 20171 recommend that blood pressure-lowering medication be used for secondary prevention in patients with cardiovascular disease and an average systolic blood pressure (SBP) ≥130 mm Hg or diastolic blood pressure (DBP) ≥80 mm Hg, and for primary prevention in adults with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk2 of ≥10% and an average SBP ≥130 mm Hg or DBP ≥80 mm Hg. A blood pressure target of <130/80 mm Hg is now recommended for such patients.

For patients with no history of cardiovascular disease and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1516
 Downloadable, electronic issue - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian